The completion of this study could positively impact Pfizer and BioNTech’s stock performance, as successful results may lead to new vaccine offerings, enhancing their market position. This development ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

Virus-based treatments are already approved to treat several types of cancer, and combining them with bacteria could make ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F.

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

They’re turning their backs on a technology thought to have saved millions of lives—with the potential to save many more.

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...